O	0	6	Impact
O	7	9	of
B-intervention	10	12	on
I-intervention	12	13	-
I-intervention	13	17	site
I-intervention	18	28	initiation
I-intervention	29	35	visits
O	36	38	on
O	39	46	patient
O	47	58	recruitment
O	59	62	and
O	63	67	data
O	68	75	quality
O	76	78	in
O	79	80	a
O	81	91	randomized
O	92	97	trial
O	98	100	of
O	101	109	adjuvant
O	110	122	chemotherapy
O	123	126	for
O	127	133	breast
O	134	140	cancer
O	140	141	.

O	142	144	To
O	145	152	provide
O	153	162	empirical
O	163	171	evidence
O	172	174	on
O	175	178	the
O	179	185	impact
O	186	188	of
O	189	191	on
O	191	192	-
O	192	196	site
O	197	207	initiation
O	208	214	visits
O	215	217	on
O	218	221	the
O	222	231	following
O	232	240	outcomes
O	240	241	:
O	242	249	patient
O	250	261	recruitment
O	261	262	,
O	263	271	quantity
O	272	275	and
O	276	283	quality
O	284	286	of
O	287	291	data
O	292	301	submitted
O	302	304	to
O	305	308	the
O	309	314	trial
O	315	327	coordinating
O	328	334	office
O	334	335	,
O	336	339	and
O	340	348	patients
O	348	349	'
O	350	356	follow
O	356	357	-
O	357	359	up
O	360	364	time
O	364	365	.

O	366	370	This
O	371	385	methodological
O	386	391	study
O	392	395	was
O	396	405	performed
O	406	408	as
O	409	413	part
O	414	416	of
O	417	418	a
O	419	429	randomized
O	430	435	trial
O	436	445	comparing
O	446	449	two
O	450	461	combination
O	462	476	chemotherapies
O	477	480	for
O	481	489	adjuvant
O	490	499	treatment
O	500	502	of
O	503	509	breast
O	510	516	cancer
O	516	517	.

O	518	525	Centers
O	526	539	participating
O	540	542	to
O	543	546	the
O	547	552	trial
O	553	557	were
O	558	568	randomized
O	569	571	to
O	572	578	either
O	579	586	receive
O	587	597	systematic
O	598	600	on
O	600	601	-
O	601	605	site
O	606	612	visits
O	613	614	(
O	614	621	Visited
O	622	627	group
O	627	628	)
O	628	629	,
O	630	632	or
B-control	633	636	not
I-control	637	638	(
I-control	638	641	Non
I-control	641	642	-
I-control	642	649	visited
I-control	650	655	group
I-control	655	656	)
O	656	657	.

O	658	661	The
O	662	667	study
O	668	671	was
O	672	682	terminated
O	683	688	after
O	689	692	two
O	693	698	years
O	698	699	,
O	700	705	while
O	706	709	the
O	710	714	main
O	715	725	randomized
O	726	731	trial
O	732	741	continued
O	741	742	.

O	743	745	Of
O	746	749	the
B-total-participants	750	753	135
O	754	761	centers
O	762	766	that
O	767	770	had
O	771	780	expressed
O	781	783	an
O	784	792	interest
O	793	795	in
O	796	799	the
O	800	805	trial
O	805	806	,
O	807	811	only
B-total-participants	812	814	69
O	815	825	randomized
O	826	828	at
O	829	834	least
O	835	838	one
O	839	846	patient
O	847	848	(
O	848	850	35
O	850	851	/
O	851	853	68
O	854	856	in
O	857	860	the
O	861	868	Visited
O	869	874	group
O	874	875	,
O	876	878	34
O	878	879	/
O	879	881	67
O	882	884	in
O	885	888	the
O	889	892	Non
O	892	893	-
O	893	900	visited
O	901	906	group
O	906	907	)
O	907	908	.

O	909	915	Almost
O	916	919	two
O	919	920	-
O	920	926	thirds
O	927	929	of
O	930	933	the
O	934	942	patients
O	943	947	were
O	948	955	entered
O	956	958	by
B-total-participants	959	961	17
O	962	969	centers
O	970	971	(
B-intervention-participants	971	973	10
O	974	976	in
O	977	980	the
O	981	988	Visited
O	989	994	group
O	994	995	,
B-control-participants	996	1001	seven
O	1002	1004	in
O	1005	1008	the
O	1009	1012	Non
O	1012	1013	-
O	1013	1020	visited
O	1021	1026	group
O	1026	1027	)
O	1028	1032	that
O	1033	1040	accrued
O	1041	1045	more
O	1046	1050	than
O	1051	1053	10
O	1054	1062	patients
O	1063	1067	each
O	1067	1068	.

O	1069	1073	None
O	1074	1076	of
O	1077	1080	the
O	1081	1093	prespecified
O	1094	1102	outcomes
O	1103	1110	favored
O	1111	1114	the
O	1115	1120	group
O	1121	1123	of
O	1124	1131	centers
O	1132	1141	submitted
O	1142	1144	to
O	1145	1147	on
O	1147	1148	-
O	1148	1152	site
O	1153	1163	initiation
O	1164	1170	visits
O	1171	1172	(
O	1172	1174	ie
O	1174	1175	,
O	1176	1180	mean
B-outcome	1181	1187	number
I-outcome	1188	1190	of
I-outcome	1191	1198	queries
I-outcome	1199	1202	par
I-outcome	1203	1210	patient
O	1210	1211	:
B-iv-cont-mean	1212	1213	6
I-iv-cont-mean	1213	1214	.
I-iv-cont-mean	1214	1215	1
O	1216	1217	+
O	1217	1218	/
O	1218	1219	-
B-iv-cont-sd	1220	1221	9
I-iv-cont-sd	1221	1222	.
I-iv-cont-sd	1222	1223	7
O	1224	1230	versus
B-cv-cont-mean	1231	1232	5
I-cv-cont-mean	1232	1233	.
I-cv-cont-mean	1233	1234	4
O	1235	1236	+
O	1236	1237	/
O	1237	1238	-
B-cv-cont-sd	1239	1240	6
I-cv-cont-sd	1240	1241	.
I-cv-cont-sd	1241	1242	4
O	1242	1243	,
O	1244	1256	respectively
O	1257	1260	for
O	1261	1264	the
O	1265	1272	Visited
O	1273	1276	and
O	1277	1280	Non
O	1280	1281	-
O	1281	1288	visited
O	1289	1295	groups
O	1295	1296	)
O	1296	1297	.

B-outcome	1298	1309	Spontaneous
I-outcome	1310	1321	transmittal
I-outcome	1322	1324	of
I-outcome	1325	1329	case
I-outcome	1330	1336	report
I-outcome	1337	1342	forms
O	1342	1343	,
O	1344	1352	although
O	1353	1361	required
O	1362	1364	by
O	1365	1373	protocol
O	1373	1374	,
O	1375	1378	was
O	1379	1382	low
O	1383	1385	in
O	1386	1390	both
O	1391	1401	randomized
O	1402	1408	groups
O	1409	1410	(
O	1410	1414	mean
O	1415	1421	number
O	1422	1424	of
O	1425	1430	pages
O	1431	1434	per
O	1435	1442	patient
O	1442	1443	:
B-iv-cont-mean	1444	1445	1
I-iv-cont-mean	1445	1446	.
I-iv-cont-mean	1446	1447	5
O	1448	1449	+
O	1449	1450	/
O	1450	1451	-
B-iv-cont-sd	1452	1453	2
I-iv-cont-sd	1453	1454	.
I-iv-cont-sd	1454	1455	0
O	1456	1462	versus
B-cv-cont-mean	1463	1464	2
I-cv-cont-mean	1464	1465	.
I-cv-cont-mean	1465	1466	1
O	1467	1468	+
O	1468	1469	/
O	1469	1470	-
B-cv-cont-sd	1471	1472	2
I-cv-cont-sd	1472	1473	.
I-cv-cont-sd	1473	1474	3
O	1474	1475	,
O	1476	1488	respectively
O	1488	1489	)
O	1489	1490	,
O	1491	1495	with
O	1496	1509	investigators
B-outcome	1510	1520	submitting
I-outcome	1521	1526	about
I-outcome	1527	1530	one
I-outcome	1530	1531	-
I-outcome	1531	1536	third
I-outcome	1537	1539	of
I-outcome	1540	1543	the
I-outcome	1544	1552	expected
I-outcome	1553	1558	forms
I-outcome	1559	1561	on
I-outcome	1562	1566	time
O	1567	1568	(
B-iv-bin-percent	1568	1570	29
I-iv-bin-percent	1570	1571	%
O	1572	1575	and
B-cv-bin-percent	1576	1578	39
I-cv-bin-percent	1578	1579	%
O	1579	1580	,
O	1581	1593	respectively
O	1593	1594	)
O	1594	1595	.

O	1596	1600	This
O	1601	1606	study
O	1607	1612	could
O	1613	1616	not
O	1617	1625	evaluate
O	1626	1629	the
O	1630	1636	impact
O	1637	1639	of
O	1640	1648	repeated
O	1649	1651	on
O	1651	1652	-
O	1652	1656	site
O	1657	1663	visits
O	1664	1666	on
O	1667	1675	clinical
O	1676	1684	outcomes
O	1684	1685	.

O	1686	1696	Systematic
O	1697	1699	on
O	1699	1700	-
O	1700	1704	site
O	1705	1715	initiation
O	1716	1722	visits
O	1723	1726	did
O	1727	1730	not
O	1731	1741	contribute
O	1742	1755	significantly
O	1756	1758	to
O	1759	1763	this
O	1764	1772	clinical
O	1773	1778	trial
O	1778	1779	.
